Merck & Co.’s new antiviral pill – once touted as a potential game changer for treating COVID-19 – is the last choice among four available options for at-risk patients given its relatively low efficacy and potential safety issues, U.S. doctors, healthcare systems and pharmacies told Reuters.
The U.S. government will make 400 million non-surgical N95 masks from its strategic national stockpile available for free to the public starting next week, a White House official said, marking the Biden administration’s latest effort to help curb the COVID-19 pandemic.
CVS Health Corp. will shut about 900 stores over the next three years as the company tries to adapt to changing consumer preferences by pivoting to new store formats that offer more health services.
CVS Health Corp. on November 3 said the company’s adjusted profit target for 2022 should largely meet Wall Street estimates, with volatile medical costs in its health insurance unit expected to stabilize after the Covid-19 crisis drove them up during 2021.
CVS Health Corp. said on Sept. 20 the company would fill as many as 25,000 clinical and retail jobs ahead of the flu season and as the United States prepares to administer booster Covid-19 vaccine shots.
Cigna Corp. said on Aug. 26 the company would now sell health insurance plans on online marketplaces created by the Affordable Care Act (ACA), popularly known as Obamacare, in three new U.S. states and 93 new counties.
PharmaLive talked to Milan Kalawadia – Senior Vice President, Head of US Commercial Operations for Dr. Reddy’s Laboratories – about facing challenges from the COVID-19 pandemic; obstacles going forward for generic drug companies; customer relationships; and other industry-related topics.
Walgreens Boots Alliance Inc. said on Aug. 4 the drugstore chain had administered more than 29 million Covid-19 vaccines at its stores so far, led by a surge in parts of the United States that had lagged in vaccinations.
The U.S. Food and Drug Administration approved Viatris and Biocon Biologics’ Semglee (insulin glargine-yfgn injection) as the first interchangeable biosimilar product, which is indicated to control high blood sugar in adults with Type 2 diabetes as well as adults and pediatric patients with Type 1 diabetes.
With a $26 billion nationwide settlement in sight over claims that the three largest U.S. drug distributors and Johnson & Johnson helped fuel a nationwide opioid epidemic, state and local governments will soon turn their attention to pharmacies and a handful of drugmakers.
